KR950032283A - 흑색종 관련 항원성 폴리펩티드, 그 에피토프 및 흑색종에 대한 백신 - Google Patents
흑색종 관련 항원성 폴리펩티드, 그 에피토프 및 흑색종에 대한 백신 Download PDFInfo
- Publication number
- KR950032283A KR950032283A KR1019950003177A KR19950003177A KR950032283A KR 950032283 A KR950032283 A KR 950032283A KR 1019950003177 A KR1019950003177 A KR 1019950003177A KR 19950003177 A KR19950003177 A KR 19950003177A KR 950032283 A KR950032283 A KR 950032283A
- Authority
- KR
- South Korea
- Prior art keywords
- nucleotide sequence
- peptide
- vaccine
- antigen
- melanoma
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 17
- 229960005486 vaccine Drugs 0.000 title claims abstract 12
- 201000001441 melanoma Diseases 0.000 title claims abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 4
- 230000000890 antigenic effect Effects 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims abstract 16
- 239000000427 antigen Substances 0.000 claims abstract 10
- 108091007433 antigens Proteins 0.000 claims abstract 10
- 102000036639 antigens Human genes 0.000 claims abstract 10
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract 4
- 238000001514 detection method Methods 0.000 claims abstract 4
- 230000000149 penetrating effect Effects 0.000 claims abstract 4
- 238000012544 monitoring process Methods 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims 14
- 125000003729 nucleotide group Chemical group 0.000 claims 14
- 239000000523 sample Substances 0.000 claims 6
- 238000010367 cloning Methods 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 3
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108700028369 Alleles Proteins 0.000 claims 1
- 108091009167 Bloom syndrome protein Proteins 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 claims 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 230000037430 deletion Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 101150067404 117 gene Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46449—Melanoma antigens
- A61K39/464492—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/82—Proteins from microorganisms
- Y10S530/822—Protozoa
Abstract
본 발명은 gp100으로 공지된 흑색종 관련 항원에 관한 것이다. 또한, 상기 항원으로부터 유래한 펩티드에 관한 것이다. Gp100과 그 펩티드는 흑색종의 치료에 사용될 수 있다. 본 발명의 또 다른 양태는 gp100 또는 숙주세포이다. 또한 본 발명은 gp100 또는 gp100-유래 펩티드를 발현시킬 수 있는 숙주 세포이다. 또한, 본 발명은 gp100을 특이적으로 인지하는 종양 침투성 림프구(TIL)에 관한 것이며, 상기 TIL을 가진 백신에 관한 것이다.
또한, 흑색종의 검출용 및 예방 접종의 모니터용 진단 물질도 본 발명의 일부를 이룬다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 인간 gp100/Pme 117 유전자 부분의 게놈 조직을 도시한 것이다. 제2도는 인간 gp100/pMel 117 부류의 구성원의 카르복시말단 서열을 도시한 것이다. 제3A도는 gp100 단백질의 gp100 결실 돌연변이체 암호부를 도시한 것이다(수치는 서열 동정 번호 2에서 제시한 gp100 단백질내 아미노산을 나타냄), 제3B도는 제3B도에 도시한 gp100 결실 돌연변이체 및 HLA-A2. 1로 형질감염된 세포의 TLL 1200에 의한 인지를 나타낸 것이다, 제4A도는 8량체~11량체 범위에서 gp100 148-166 영역으로부터 유도된 5개 펩티드를 TIL 1200에 의한 인지에 대해 시험한 것이다. 제4B도는 제4A도에 명시한 gp100 펩티드의 TIL 1200에 의한 인식에 대한 적정(E/T 비율 30:1) 결과를 도시한 것이다, 제5도는 HLA-A2.1에 대한 비루스 에피토프 및 gp100의 결합을 나타낸 것이다.
Claims (33)
- 서열 동정 번호 2의 아미노산 서열을 포함하는 것을 특징으로 하는 흑색종 관련 항원.
- 제1항에 따른 항원을 암호화하는 뉴클레오티드 서열을 포함하는 것을 특징으로 하는 뉴클레오티드 서열.
- 제2항에 있어서, 서열 동정 번호 1의 뉴클레오티드 서열을 포함하는 것을 특징으로 하는 뉴클레오티드 서열.
- 제1항에 따른 항원의 면역원성 단편을 포함하는 것을 특징으로 하는 면역원성 펩티드.
- L-L-D-G-T-AT-L-R-L, V-L-P-D-G-Q-V-I-W-V, T-W-G-Q-Y-W-Q-V, V-W-K-T-W-G-Q-Y-W-Q-V, K-T-W-G-Q-Y-W-Q-V-L, K-T-W-G-Q-Y-W-Q-V 및 T-W-G-Q-Y-W-Q-V-L로 구성된 군에 선택되는 아미노산 서열을 포함하는 것을 특징으로 하는 면역원성 펩티드.
- 제5항에 따른 펩티드를 암호화하는 뉴클레오티드 서열을 포함하는 것을 특징으로 하는 뉴클레오티드 서열.
- 제6항에 있어서, 서열 동정 번호 3, 5, 7 및 9의 서열로 구성된 군에서 선택된 뉴클레오티드 서열을 포함하는 것을 특징으로 하는 뉴클레오티드 서열.
- 제2항 또는 제3항에 따른 뉴클레오티드 서열 또는 그 상보성 서열을 지향한 표지된 프로브 및 1종 이상의 프라이머를 포함하는 것을 특징으로 하는 흑색종 세포의 검출용 시험 키트.
- a.환자에게서 샘플을 수득하는 단계; b. 상기 샘플에 제2항 또는 제3항에 따른 뉴클레오티드 서열 또는 이 서열의 일부의 증폭을 일으키는 단계; c. 증폭된 핵산을 표지된 상보적인 표지된 프로브와 반응시키는 단계; d. 상기 표지를 검출하는 단계를 포함하는 것을 특징으로 하는 흑색종 세포의 검출 방법.
- 제2항, 제3항, 제6항 또는 제7항중 어느 한 항에 따른 뉴클레오티드 서열을 포함하는 클로닝 매체(vehicle)
- 제10항에 따른 클로닝 매체로 형질 감염되거나 또는 형질 전환되며, 바람직하게는 MHC 1류 대립 유전자를 암호화하는 뉴클레오티드 서열을 포함하는 클로닝 매체로 동시 형질 감염된 것을 특징으로 하는 숙주 세포.
- 제11항에 있어서, 쥐 EL4 및 P8.15 세포, 및 인간 BLM 세포로 구성된 군에서 선택되는 것을 특징으로 하는 숙주 세포.
- 제11항 또는 제12항에 있어서, 항원 제공 세포인 것을 특징으로 하는 숙주 세포.
- 제11항 내지 제13항중 어느 한 항에 있어서, 추가로 공통-자극 분자를 생성시키는 것을 특징으로 하는 숙주 세포.
- 제1항에 따른 항원, 또는 그 에피토프를 포함하는 것을 특징으로 하는 백신.
- 제4항에 따른 펩티드를 포함하는 것을 특징으로 하는 백신.
- 제16항에 있어서, 제5항에 따른 펩티드를 포함하는 것을 특징으로 하는 백신.
- 제15항 내지 제17항중 어느 한 항에 있어서, 상기 펩티드가 약학적 허용 담체 또는 부형제와 혼합된 것을 특징으로 하는 백신.
- 제15항 내지 제17항중 어느 한 항에 있어서, 상기 펩티드가 사전에 부가된 항원 제공 세포를 포함하는 것을 특징으로 하는 백신.
- 제11항 내지 제13항중 어느 한 항에 따른 숙주 세포를 포함하는 것을 특징으로 하는 백신.
- 제2항, 제3항, 제6항 또는 제7항중 어느 한 항에 따른 뉴클레오티드 서열을 포함하는 것을 특징으로 하는 백신.
- 제1항, 제4항 또는 제5항중 어느 한 항에 따른 펩티드에 대한 T 세포 수용기 이 T 세포 수용기를 발현시키는 세포를 포함하는 것을 특징으로 하는 백신.
- 제15항 내지 제22항중 어느 한 항에 있어서, 보조제; 1종 이상의 사이토카인; CD2, CD3, CD27, CD28 또는 기타 T 세포 표면 항원에 대한 항체; 및 CD4+ 또는 CD8+ T 세포를 자극하는 헬피에피토프로 구성된 군에서 선택되는 1종 이상의 화합물을 추가로 포함하는 것을 특징으로 하는 백신.
- a. 환자로부터 흑색종 샘플을 채취하는 단계, b. 상기 샘플로부터 종양 침투성 림프구를 분리하는 단계; c. 상기 림프구를 제1항에 따른 항원과 반응시키는 단계; d. 상기 항원에 결합하는 림프구를 분리하는 단계를 포함하는 것을 특징으로 하는 항원 반응성의 종양 침투성 림프구를 생성시키는 방법.
- 제1항에 따른 항원에 결합할 수 있는 것을 특징으로 하는 종양 침투성 림프구.
- 릭포카인을 암호화하는 뉴클레오티드 서열을 갖는 클로닝 매체로 형질 감염된 것을 특징으로 하는 제1항에 따른 항원을 발현시킬 수 있는 흑색종 세포.
- 제25항에 따른 종양 침투성 림프구, 제26항에 따른 흑색종 세포 또는 그 둘다를 포함하는 것을 특징으로 하는 백신.
- 제1항, 제4항 또는 제5항중 어느 한 항에 따른 펩티드를 사용하는 것을 특징으로 하는 펩티드와 검출용 마커의 접합체.
- 제28항에 있어서, 검출용 마커가 방사 핵종인 것을 특징으로 하는 접합체.
- 제4항 또는 제5항에 따른 펩티드에 대한 항체인 것을 특징으로 항체.
- 제30항에 따른 항체를 포함하는 것을 특징으로 하는 백신.
- 제4항 또는 제5항에 따른 펩티드에 대한 항체의 존재를 환자의 혈청으로부터 검출하는 것을 특징으로 하는, 면역 치료를 모니터하는 방법.
- 제28항 또는 제29항에 따른 접합체를 포함하는 것을 특징으로 하는 제30항에 따른 항체의 검출용 키트.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94200337 | 1994-02-16 | ||
| EP94200337.7 | 1994-02-16 | ||
| EP94203709.4 | 1994-12-21 | ||
| EP94203709 | 1994-12-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR950032283A true KR950032283A (ko) | 1995-12-20 |
| KR100380503B1 KR100380503B1 (ko) | 2003-07-02 |
Family
ID=26136040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019950003177A KR100380503B1 (ko) | 1994-02-16 | 1995-02-16 | 흑색종관련항원성폴리펩티드,그에피토프및흑색종에대한백신 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US6500919B1 (ko) |
| EP (1) | EP0668350B2 (ko) |
| JP (1) | JP3869476B2 (ko) |
| KR (1) | KR100380503B1 (ko) |
| AT (1) | ATE272113T1 (ko) |
| AU (1) | AU697267B2 (ko) |
| CA (1) | CA2142575C (ko) |
| DE (1) | DE69533295T3 (ko) |
| DK (1) | DK0668350T4 (ko) |
| ES (1) | ES2224113T5 (ko) |
| FI (1) | FI121572B (ko) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5882654A (en) * | 1989-11-03 | 1999-03-16 | Morton; Donald L. | Polyvalent melanoma vaccine |
| US5840317A (en) * | 1989-11-03 | 1998-11-24 | Morton; Donald L. | Composition comprising tumor cell lines containing GD2 ganglioside GM2 ganglioside, M-TAA, and either M-urinary antigen or M-fetal antigen |
| CA2072620C (en) * | 1989-11-03 | 2007-06-12 | Donald L. Morton | Urinary tumor associated antigen, antigenic subunits uses and methods of detection |
| US5858689A (en) * | 1993-07-22 | 1999-01-12 | Ludwig Institute For Cancer Research | Isolated peptides derived from the gage tumor rejection antigen precursor and uses thereof |
| EP0668350B2 (en) * | 1994-02-16 | 2008-12-03 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| EP1630229B1 (en) | 1994-04-22 | 2013-04-03 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| US5843648A (en) * | 1995-01-10 | 1998-12-01 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services | P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods |
| US7501501B2 (en) | 1995-09-26 | 2009-03-10 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | MHC-Class II restricted melanoma antigens and their use in therapeutic methods |
| US6951917B1 (en) | 1995-09-26 | 2005-10-04 | The United States Of America As Represented By The Department Of Health And Human Services | MHC-class II restricted melanoma antigens and their use in therapeutic methods |
| US20040156861A1 (en) * | 1996-07-11 | 2004-08-12 | Figdor Carl Gustav | Melanoma associated peptide analogues and vaccines against melanoma |
| ZA975858B (en) * | 1996-07-11 | 1998-09-01 | Akzo Nobel Nv | Melanoma associated peptide analogues and vaccines against melanoma |
| JP2001517206A (ja) * | 1996-08-16 | 2001-10-02 | ザ ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン | 免疫優性な共有黒色腫抗原を発現する黒色腫細胞株およびその使用方法 |
| AU6557501A (en) * | 1996-08-16 | 2001-11-15 | Johns Hopkins University School Of Medicine, The | Melanoma cell lines expressing shared immunodominant melanoma antigens and methods of using same |
| CA2242590A1 (en) * | 1996-10-04 | 1998-04-09 | Thomas Jefferson University | T cells mediating an immune response and methods of use |
| US20060034844A1 (en) * | 1996-12-04 | 2006-02-16 | The Regents Of The University Of California | Stimulation of T cells against self antigens using CTLA-4 blocking agents |
| US20020029391A1 (en) * | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| CA2334958A1 (en) * | 1998-12-24 | 2000-07-06 | New York Medical College | Peptide mimics useful for treating disease |
| EP1268542A2 (en) * | 2000-03-20 | 2003-01-02 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
| CA2411040A1 (en) | 2000-05-31 | 2001-12-06 | Genzyme Corporation | Therapeutic anti-melanoma compounds |
| AU2001268159B2 (en) * | 2000-06-02 | 2005-09-15 | Eisai Inc. | Delivery systems for bioactive agents |
| WO2002056910A1 (en) | 2001-01-17 | 2002-07-25 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| AU2002305138A1 (en) * | 2001-04-09 | 2002-10-21 | Mayo Foundation For Medical Education And Research | Methods and materials for cancer treatment |
| EP2305699B1 (de) * | 2001-06-05 | 2014-08-13 | CureVac GmbH | Stabilisierte mRNA mit erhöhtem G/C-Gehalt und optimierter Codon Usage für die Impfung gegen Schlafkrankheit, Leishmaniose und Toxoplasmose |
| US7340349B2 (en) | 2001-07-25 | 2008-03-04 | Jonathan Bingham | Method and system for identifying splice variants of a gene |
| US7833779B2 (en) | 2001-07-25 | 2010-11-16 | Jivan Biologies Inc. | Methods and systems for polynucleotide detection |
| DE10162480A1 (de) | 2001-12-19 | 2003-08-07 | Ingmar Hoerr | Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen |
| IL153954A0 (en) * | 2003-01-14 | 2003-07-31 | Hadasit Med Res Service | IMMUNOTHERAPY OF METASTATIC MELANOMA WITH AUTOLOGOUS DENDRITIC CELLS LOADED WITH HYDROPHILIC RECOMBINANT gp100 PROTIEN (HR-gp100) |
| RU2267496C2 (ru) * | 2004-01-15 | 2006-01-10 | Сергей Иванович Черныш | Противоопухолевые и антивирусные пептиды |
| US20070154889A1 (en) * | 2004-06-25 | 2007-07-05 | Veridex, Llc | Methods and reagents for the detection of melanoma |
| DE102004042546A1 (de) * | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| AT502292B1 (de) * | 2005-05-11 | 2010-04-15 | Avir Green Hills Biotechnology | Melanomdiagnose |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| ES2737960T3 (es) | 2010-10-01 | 2020-01-17 | Modernatx Inc | Nucleósidos, nucleótidos y ácidos nucleicos modificados y sus usos |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2848209C (en) * | 2011-09-15 | 2021-06-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors recognizing hla-a1- or hla-cw7-restricted mage |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| EP2791160B1 (en) | 2011-12-16 | 2022-03-02 | ModernaTX, Inc. | Modified mrna compositions |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| WO2013188831A1 (en) | 2012-06-15 | 2013-12-19 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| EP4074834A1 (en) | 2012-11-26 | 2022-10-19 | ModernaTX, Inc. | Terminally modified rna |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| US20160024493A1 (en) | 2013-03-15 | 2016-01-28 | Adaptive Biotechnologies Corporation | Uniquely tagged rearranged adaptive immune receptor genes in a complex gene set |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA2926218A1 (en) | 2013-10-03 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotides encoding low density lipoprotein receptor |
| CA2925021A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Ag | Modified rna with decreased immunostimulatory properties |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US144482A (en) * | 1873-11-11 | Improvement in wood-sawing machines | ||
| US76392A (en) * | 1868-04-07 | Theebnce bqutte | ||
| US4497796A (en) * | 1980-03-26 | 1985-02-05 | The Regents Of The University Of California | Gene transfer in intact mammals |
| US4727028A (en) * | 1981-06-22 | 1988-02-23 | Eli Lilly And Company | Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof |
| US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
| US4485086A (en) * | 1983-04-11 | 1984-11-27 | Wong Dennis W | Radiolabeled tumor imaging agent and method of preparation |
| US5190931A (en) * | 1983-10-20 | 1993-03-02 | The Research Foundation Of State University Of New York | Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA |
| US5208149A (en) * | 1983-10-20 | 1993-05-04 | The Research Foundation Of State University Of New York | Nucleic acid constructs containing stable stem and loop structures |
| DE3483252D1 (de) * | 1983-12-05 | 1990-10-25 | Asahi Chemical Ind | Verfahren zur induktion von antitumorimmunozyten, verfahren zur herstellung von antitumorimmunozyten und durch das verfahren hergestellte antitumorimmunozyten. |
| US4740463A (en) * | 1984-04-13 | 1988-04-26 | Massachusetts Institute Of Technology | Methods and artificial genes for antagonizing the function of an oncogene |
| EP0174608A1 (en) * | 1984-09-13 | 1986-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Beta-actin gene and regulatory elements, preparation and use |
| US5262177A (en) * | 1986-02-07 | 1993-11-16 | Oncogen | Recombinant viruses encoding the human melanoma-associated antigen |
| US5188943A (en) * | 1988-11-07 | 1993-02-23 | Synergen, Inc. | Method of producing high molecular weight human fibroblast growth factors |
| US5176900A (en) * | 1990-12-18 | 1993-01-05 | The Procter & Gamble Company | Compositions for reducing calculus |
| US5342774A (en) * | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| US5518913A (en) * | 1991-10-10 | 1996-05-21 | National Research Council Of Canada | High level recombinant protein production using conditional helper-free adenovirus vector |
| US5376531A (en) * | 1992-09-03 | 1994-12-27 | Northwestern University | Method of detecting cancer |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| EP0668350B2 (en) * | 1994-02-16 | 2008-12-03 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Melanoma associated antigenic polypeptide, epitopes thereof and vaccines against melanoma |
| US5731172A (en) * | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5874560A (en) * | 1994-04-22 | 1999-02-23 | The United States Of America As Represented By The Department Of Health And Human Services | Melanoma antigens and their use in diagnostic and therapeutic methods |
| EP1630229B1 (en) * | 1994-04-22 | 2013-04-03 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Melanoma antigens |
| ATE336587T1 (de) * | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| DK0707071T3 (da) * | 1994-08-16 | 2003-11-17 | Crucell Holland Bv | Rekombinante vektorer afledt fra adenovirus til anvendelse i genterapi |
| SI0833934T2 (sl) * | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
| US5837511A (en) * | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
| US5783567A (en) * | 1997-01-22 | 1998-07-21 | Pangaea Pharmaceuticals, Inc. | Microparticles for delivery of nucleic acid |
| US5891432A (en) * | 1997-07-29 | 1999-04-06 | The Immune Response Corporation | Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same |
| US6291430B1 (en) * | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US5965535A (en) * | 1997-09-12 | 1999-10-12 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US5965381A (en) * | 1998-03-06 | 1999-10-12 | Ludwig Institute For Cancer Research | Delivery of proteins into eukaryotic cells with recombinant yersinia |
| US6245525B1 (en) * | 1998-07-27 | 2001-06-12 | Ludwig Institute For Cancer Research | Tumor associated nucleic acids and uses therefor |
| US6407063B1 (en) * | 1998-10-02 | 2002-06-18 | Ludwig Institute For Cancer Research | Tumor antigens and CTL clones isolated by a novel procedure |
-
1995
- 1995-02-14 EP EP95200348A patent/EP0668350B2/en not_active Expired - Lifetime
- 1995-02-14 DK DK95200348T patent/DK0668350T4/da active
- 1995-02-14 DE DE69533295T patent/DE69533295T3/de not_active Expired - Lifetime
- 1995-02-14 AT AT95200348T patent/ATE272113T1/de active
- 1995-02-14 ES ES95200348T patent/ES2224113T5/es not_active Expired - Lifetime
- 1995-02-15 US US08/388,852 patent/US6500919B1/en not_active Expired - Lifetime
- 1995-02-15 CA CA2142575A patent/CA2142575C/en not_active Expired - Lifetime
- 1995-02-15 FI FI950665A patent/FI121572B/fi not_active IP Right Cessation
- 1995-02-15 AU AU12272/95A patent/AU697267B2/en not_active Expired
- 1995-02-16 KR KR1019950003177A patent/KR100380503B1/ko not_active IP Right Cessation
- 1995-02-16 JP JP02838795A patent/JP3869476B2/ja not_active Expired - Lifetime
-
2002
- 2002-05-01 US US10/136,145 patent/US20030216559A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU1227295A (en) | 1995-08-24 |
| US20030216559A1 (en) | 2003-11-20 |
| DE69533295T2 (de) | 2005-07-28 |
| FI950665A0 (fi) | 1995-02-15 |
| JP3869476B2 (ja) | 2007-01-17 |
| ES2224113T3 (es) | 2005-03-01 |
| DK0668350T3 (da) | 2004-11-29 |
| EP0668350B1 (en) | 2004-07-28 |
| CA2142575C (en) | 2011-01-04 |
| DK0668350T4 (da) | 2009-02-23 |
| EP0668350A1 (en) | 1995-08-23 |
| FI121572B (fi) | 2011-01-14 |
| CA2142575A1 (en) | 1995-08-17 |
| DE69533295T3 (de) | 2009-07-16 |
| EP0668350B2 (en) | 2008-12-03 |
| ATE272113T1 (de) | 2004-08-15 |
| FI950665A (fi) | 1995-08-17 |
| AU697267B2 (en) | 1998-10-01 |
| ES2224113T5 (es) | 2009-05-01 |
| KR100380503B1 (ko) | 2003-07-02 |
| US6500919B1 (en) | 2002-12-31 |
| JPH07278193A (ja) | 1995-10-24 |
| DE69533295D1 (de) | 2004-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR950032283A (ko) | 흑색종 관련 항원성 폴리펩티드, 그 에피토프 및 흑색종에 대한 백신 | |
| US9782495B2 (en) | Proteins expressed by Mycobacterium tuberculosis and not by BCG and their use as diagnostic reagents and vaccines | |
| ATE420180T1 (de) | Verbindungen zur immuntherapie und diagnose von tuberkulose und methoden zu deren verwendung | |
| CA2230885A1 (en) | Compounds and methods for immunotherapy and diagnosis of tuberculosis | |
| JP2905170B2 (ja) | オリゴマー化ペプチド−ｍｈｃ分子複合体 | |
| JP4270523B2 (ja) | 乳癌の処置および診断のための組成物および方法 | |
| CA2209360A1 (en) | Recombinant monoclonal anti-idiotype antibody 3h1 sequences relating to human carcinoembryonic antigen | |
| Chen et al. | CTL recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. | |
| Melief et al. | Potential immunogenicity of oncogene and tumor suppressor gene products | |
| WO2001079274B1 (en) | Tuberculosis antigens and methods of use thereof | |
| US8946171B2 (en) | Immunization of an individual against carcinomas and the preliminary stages thereof | |
| US20060263389A1 (en) | Methods and compositions to enhance immune responses via recall antigens | |
| CA2259944A1 (en) | Melanoma associated peptide analogues and vaccines against melanoma | |
| WO2000044775A2 (en) | Identification of broadly reactive hla restricted t cell epitopes | |
| JPH10511985A (ja) | ヒトグルタミン酸デカルボキシラーゼ（ｇａｄ）からの自己反応性ペプチド | |
| Found | Patent Report | |
| JPH11509538A (ja) | Ｉｎ ｖｉｖｏ 糖尿病試験 | |
| Taechaudomtavorn | The interaction of paramyxovirus membrane protein with actin: a novel model to study virus-induced autoimmunity. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| N231 | Notification of change of applicant | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130322 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20140324 Year of fee payment: 12 |
|
| EXPY | Expiration of term |